Viome Life Sciences, a Bellevue-based longevity company focused on developing individualized health solutions, has closed its oversubscribed $86.5 million Series C funding round, bringing its total venture capital to $175 million. The funding will be used to develop and expand its suite of personalized health tests. The announcement coincides with the launch of Viome’s Gut Intelligence Test into 200 CVS locations nationwide.
Viome uses science to compute outcomes for consumers based on their unique human and microbial gene expressions. Its platform uses AI to analyze gene expression data from more than 600,000 samples, allowing Viome to develop at-home tests and custom health products that provide individuals with precise nutrition for their bodies.
Viome aims to redefine aging itself, enabling everyone to thrive in health and vitality. Investors including Khosla Ventures, Bold Capital and WRG Ventures participated in the company’s latest round.
